lenvatinib and Osteonecrosis

Topics: Adverse Drug Reaction Reporting Systems; Aged; Angiogenesis Inhibitors; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Everolimus; Female; Glucocorticoids; Humans; Incidence; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pharmacovigilance; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Risk Assessment; Risk Factors

Medication-related osteonecrosis of the jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to bone-targeting agents such as anti-resorptive and anti-angiogenic agents. Several MRONJ cases have been reported after dental extractions in patients under treatment with anti-angiogenic agents, including receptor activator of nuclear factor κB ligand (RANKL) inhibitor, anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors (TKIs). The aim of this article was to describe an original case of lenvatinib-related osteonecrosis of the jaw in a patient affected by thyroid cancer. A 58-year-old man diagnosed with Hurthle cell thyroid cancer, who was undergoing treatment with lenvatinib, developed maxillary osteonecrosis after a dental extraction. No other concomitant local or systemic risk factors for MRONJ were present. With new cancer therapies applied every year, it is important to note this novel case of lenvatinib osteonecrosis of the jaw in a patient undergoing cancer treatment.

Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Male; Middle Aged; Osteonecrosis; Phenylurea Compounds; Quinolines